817 related articles for article (PubMed ID: 15533764)
1. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
2. CpG-island methylation and epigenetic control of resistance to chemotherapy.
Teodoridis JM; Strathdee G; Plumb JA; Brown R
Biochem Soc Trans; 2004 Dec; 32(Pt 6):916-7. PubMed ID: 15506923
[TBL] [Abstract][Full Text] [Related]
3. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
Lin X; Asgari K; Putzi MJ; Gage WR; Yu X; Cornblatt BS; Kumar A; Piantadosi S; DeWeese TL; De Marzo AM; Nelson WG
Cancer Res; 2001 Dec; 61(24):8611-6. PubMed ID: 11751372
[TBL] [Abstract][Full Text] [Related]
4. Gene silencing by DNA methylation in haematological malignancies.
Boultwood J; Wainscoat JS
Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
6. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis.
Clark SJ
Hum Mol Genet; 2007 Apr; 16 Spec No 1():R88-95. PubMed ID: 17613553
[TBL] [Abstract][Full Text] [Related]
7. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
Baylin SB
Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
Grønbaek K; Treppendahl M; Asmar F; Guldberg P
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
[TBL] [Abstract][Full Text] [Related]
9. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Esteller M
Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
[TBL] [Abstract][Full Text] [Related]
10. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of the MGMT gene in cancer.
Soejima H; Zhao W; Mukai T
Biochem Cell Biol; 2005 Aug; 83(4):429-37. PubMed ID: 16094446
[TBL] [Abstract][Full Text] [Related]
12. The fundamental role of epigenetics in hematopoietic malignancies.
Galm O; Herman JG; Baylin SB
Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic changes in cancer.
Grønbaek K; Hother C; Jones PA
APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
16. The dialectics of cancer: A theory of the initiation and development of cancer through errors in RNAi.
Wynter CV
Med Hypotheses; 2006; 66(3):612-35. PubMed ID: 16359827
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
19. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
20. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.
Lyko F; Brown R
J Natl Cancer Inst; 2005 Oct; 97(20):1498-506. PubMed ID: 16234563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]